3. GOOD HEALTH AND WELL-BEING

Truist Financial Increases Encompass Health (NYSE:EHC) Price Target to $86.00

Written by Amanda

Encompass Health (NYSE:EHCGet Free Report) had its price target raised by equities researchers at Truist Financial from $82.00 to $86.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 17.92% from the company’s current price.

Several other brokerages also recently weighed in on EHC. Stephens reissued an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. Mizuho raised their price target on shares of Encompass Health from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $83.00 target price on shares of Encompass Health in a research note on Friday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and a consensus price target of $79.89.

Get Our Latest Stock Report on Encompass Health

Encompass Health Price Performance

Shares of EHC opened at $72.93 on Friday. The company has a market capitalization of $7.31 billion, a P/E ratio of 21.02, a price-to-earnings-growth ratio of 1.40 and a beta of 0.92. The company has a quick ratio of 1.27, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. The firm has a 50 day moving average of $68.70 and a 200 day moving average of $67.50. Encompass Health has a twelve month low of $51.15 and a twelve month high of $76.84.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CFO Douglas E. Coltharp sold 11,215 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $63.39, for a total value of $710,918.85. Following the transaction, the chief financial officer now owns 116,293 shares of the company’s stock, valued at $7,371,813.27. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

Institutional Trading of Encompass Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Encompass Health by 1.2% during the third quarter. Vanguard Group Inc. now owns 9,653,180 shares of the company’s stock worth $436,613,000 after purchasing an additional 111,745 shares in the last quarter. William Blair Investment Management LLC grew its position in shares of Encompass Health by 6.4% during the third quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock worth $381,226,000 after purchasing an additional 342,512 shares in the last quarter. Invesco Ltd. grew its position in shares of Encompass Health by 22.3% during the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock worth $266,914,000 after purchasing an additional 724,544 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Encompass Health by 4.4% during the first quarter. JPMorgan Chase & Co. now owns 3,144,147 shares of the company’s stock worth $170,098,000 after purchasing an additional 133,885 shares in the last quarter. Finally, Baupost Group LLC MA grew its position in shares of Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock worth $213,330,000 after purchasing an additional 2,283,900 shares in the last quarter. Hedge funds and other institutional investors own 92.66% of the company’s stock.

Encompass Health Company Profile

(Get Free Report)

Encompass Health Corporation provides post-acute healthcare services in the United States. It provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

Featured Articles

Analyst Recommendations for Encompass Health (NYSE:EHC)



Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

Encompass Health (NYSE:EHCGet Free Report) had its price target raised by equities researchers at Truist Financial from $82.00 to $86.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 17.92% from the company’s current price.

Several other brokerages also recently weighed in on EHC. Stephens reissued an “overweight” rating and set a $85.00 price target on shares of Encompass Health in a research report on Tuesday, January 16th. Mizuho raised their price target on shares of Encompass Health from $77.00 to $82.00 and gave the company a “buy” rating in a research report on Friday. William Blair reaffirmed an “outperform” rating on shares of Encompass Health in a research report on Wednesday. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $83.00 target price on shares of Encompass Health in a research note on Friday. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Encompass Health currently has a consensus rating of “Buy” and a consensus price target of $79.89.

Get Our Latest Stock Report on Encompass Health

Encompass Health Price Performance

Shares of EHC opened at $72.93 on Friday. The company has a market capitalization of $7.31 billion, a P/E ratio of 21.02, a price-to-earnings-growth ratio of 1.40 and a beta of 0.92. The company has a quick ratio of 1.27, a current ratio of 1.28 and a debt-to-equity ratio of 1.19. The firm has a 50 day moving average of $68.70 and a 200 day moving average of $67.50. Encompass Health has a twelve month low of $51.15 and a twelve month high of $76.84.

Insider Buying and Selling at Encompass Health

In other Encompass Health news, CFO Douglas E. Coltharp sold 11,215 shares of the stock in a transaction dated Monday, November 13th. The stock was sold at an average price of $63.39, for a total value of $710,918.85. Following the transaction, the chief financial officer now owns 116,293 shares of the company’s stock, valued at $7,371,813.27. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 1.90% of the stock is owned by corporate insiders.

Institutional Trading of Encompass Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its position in shares of Encompass Health by 1.2% during the third quarter. Vanguard Group Inc. now owns 9,653,180 shares of the company’s stock worth $436,613,000 after purchasing an additional 111,745 shares in the last quarter. William Blair Investment Management LLC grew its position in shares of Encompass Health by 6.4% during the third quarter. William Blair Investment Management LLC now owns 5,676,379 shares of the company’s stock worth $381,226,000 after purchasing an additional 342,512 shares in the last quarter. Invesco Ltd. grew its position in shares of Encompass Health by 22.3% during the third quarter. Invesco Ltd. now owns 3,974,306 shares of the company’s stock worth $266,914,000 after purchasing an additional 724,544 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of Encompass Health by 4.4% during the first quarter. JPMorgan Chase & Co. now owns 3,144,147 shares of the company’s stock worth $170,098,000 after purchasing an additional 133,885 shares in the last quarter. Finally, Baupost Group LLC MA grew its position in shares of Encompass Health by 318.9% during the first quarter. Baupost Group LLC MA now owns 3,000,000 shares of the company’s stock worth $213,330,000 after purchasing an additional 2,283,900 shares in the last quarter. Hedge funds and other institutional investors own 92.66% of the company’s stock.

Encompass Health Company Profile

(Get Free Report)

Encompass Health Corporation provides post-acute healthcare services in the United States. It provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.

Featured Articles

Analyst Recommendations for Encompass Health (NYSE:EHC)



Receive News & Ratings for Encompass Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Encompass Health and related companies with MarketBeat.com’s FREE daily email newsletter.

Source: defenseworld.net

About the author

Amanda

Hi there, I am Amanda and I work as an editor at impactinvesting.ai;  if you are interested in my services, please reach me at amanda.impactinvesting.ai

Leave a Comment